Drugs / V3-Myoma
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03550703 | Jun 2018 → Dec 2019 | fibroma, leiomyoma | Immunitor LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V3-Myoma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03550703 ↗ |
| Modality | Vaccine | “V3-Myoma therapeutic vaccine” NCT03550703 ↗ |
| Route | Oral | “When administered orally, V3-Myoma should cause a specific anti-tumor immune response” NCT03550703 ↗ |